Riboscience

Executive Summary

Riboscience is a privately held San Diego-based company pioneering RNA-based therapeutics to address previously untreatable diseases. Founded in 2016, the company has developed an innovative platform that accelerates drug discovery through precision medicine, enabling targeted therapies for conditions with high unmet need. Riboscience is currently in Phase 2 clinical development, advancing its lead candidate toward proof-of-concept data. The RNA therapeutics market is rapidly expanding, and Riboscience's platform positions it to capitalize on this growth. With a focus on diseases lacking effective treatments, the company's approach has the potential to transform patient care. However, as a private entity, Riboscience faces challenges typical of clinical-stage biotechs, including capital requirements and regulatory hurdles. The upcoming milestones will be critical in determining its trajectory and value proposition.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical data readout for lead asset30% success
• Q2 2026Series C financing round closure70% success
• Q3 2026Strategic partnership or licensing deal for platform technology50% success